Nationwide Fund Advisors Reduces Position in Alnylam Pharmaceuticals Inc. (ALNY)
Nationwide Fund Advisors cut its position in shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) by 13.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 46,039 shares of the biopharmaceutical company’s stock after selling 7,436 shares during the period. Nationwide Fund Advisors owned about 0.05% of Alnylam Pharmaceuticals worth $2,555,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Schroder Investment Management Group increased its stake in Alnylam Pharmaceuticals by 235.0% in the second quarter. Schroder Investment Management Group now owns 18,592 shares of the biopharmaceutical company’s stock worth $1,032,000 after buying an additional 13,042 shares in the last quarter. Broderick Brian C increased its stake in Alnylam Pharmaceuticals by 20.3% in the second quarter. Broderick Brian C now owns 5,982 shares of the biopharmaceutical company’s stock worth $331,000 after buying an additional 1,010 shares in the last quarter. Hemenway Trust Co LLC increased its stake in Alnylam Pharmaceuticals by 4.1% in the second quarter. Hemenway Trust Co LLC now owns 13,200 shares of the biopharmaceutical company’s stock worth $732,000 after buying an additional 525 shares in the last quarter. Fayerweather Charles increased its stake in Alnylam Pharmaceuticals by 3.5% in the second quarter. Fayerweather Charles now owns 4,165 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 140 shares in the last quarter. Finally, Turner Investments L.P. bought a new stake in Alnylam Pharmaceuticals during the second quarter worth about $575,000. Institutional investors own 85.96% of the company’s stock.
Shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) traded up 2.962% during midday trading on Monday, hitting $35.285. The company had a trading volume of 730,706 shares. The company’s market capitalization is $3.02 billion. Alnylam Pharmaceuticals Inc. has a 12-month low of $33.16 and a 12-month high of $110.75. The company’s 50-day moving average price is $70.69 and its 200 day moving average price is $66.05.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.24) by $0.19. The firm earned $8.70 million during the quarter, compared to analyst estimates of $8.09 million. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The company’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter last year, the business posted ($0.85) EPS. Equities research analysts predict that Alnylam Pharmaceuticals Inc. will post ($4.68) earnings per share for the current fiscal year.
A number of research firms recently issued reports on ALNY. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Cowen and Company reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Leerink Swann reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, June 12th. Morgan Stanley downgraded Alnylam Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $38.00 to $36.00 in a research report on Friday. Finally, Jefferies Group lowered their target price on Alnylam Pharmaceuticals from $86.00 to $58.00 and set a “buy” rating on the stock in a research report on Thursday. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $80.88.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total value of $1,950,468.19. Following the completion of the sale, the chief executive officer now owns 148,465 shares in the company, valued at approximately $9,604,200.85. The transaction was disclosed in a document filed with the SEC, which is available at this link. 4.00% of the stock is currently owned by company insiders.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.